[go: up one dir, main page]

EP1171078A4 - Zusammensetzungen und verfahren zur beeinflussung der blutspiegel von high density lipoprotein (hdl) cholesterol und apolipoprotein ai, very low density liporotein (vldl) cholesterol und low density lipoprotein (ldl) cholesterol - Google Patents

Zusammensetzungen und verfahren zur beeinflussung der blutspiegel von high density lipoprotein (hdl) cholesterol und apolipoprotein ai, very low density liporotein (vldl) cholesterol und low density lipoprotein (ldl) cholesterol

Info

Publication number
EP1171078A4
EP1171078A4 EP00918362A EP00918362A EP1171078A4 EP 1171078 A4 EP1171078 A4 EP 1171078A4 EP 00918362 A EP00918362 A EP 00918362A EP 00918362 A EP00918362 A EP 00918362A EP 1171078 A4 EP1171078 A4 EP 1171078A4
Authority
EP
European Patent Office
Prior art keywords
cholesterol
lipoproteins
rate
density lipoproteins
apolipoproteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP00918362A
Other languages
English (en)
French (fr)
Other versions
EP1171078A2 (de
Inventor
Michael Jaye
Kevin J Lynch
Dilip V Amin
Kim-Anh Thi Doan
Dawn Marchadier
Cyrille Maugeais
Daniel J Rader
John A Krawiec
Victoria J South
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
University of Pennsylvania Penn
Original Assignee
Aventis Pharmaceuticals Inc
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/277,401 external-priority patent/US7008776B1/en
Application filed by Aventis Pharmaceuticals Inc, University of Pennsylvania Penn filed Critical Aventis Pharmaceuticals Inc
Publication of EP1171078A2 publication Critical patent/EP1171078A2/de
Publication of EP1171078A4 publication Critical patent/EP1171078A4/de
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP00918362A 1999-03-26 2000-03-24 Zusammensetzungen und verfahren zur beeinflussung der blutspiegel von high density lipoprotein (hdl) cholesterol und apolipoprotein ai, very low density liporotein (vldl) cholesterol und low density lipoprotein (ldl) cholesterol Ceased EP1171078A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/277,401 US7008776B1 (en) 1996-12-06 1999-03-26 Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
US277401 1999-03-26
PCT/US2000/007870 WO2000057837A2 (en) 1999-03-26 2000-03-24 Compositions and methods for effecting the levels of cholesterol

Publications (2)

Publication Number Publication Date
EP1171078A2 EP1171078A2 (de) 2002-01-16
EP1171078A4 true EP1171078A4 (de) 2002-11-06

Family

ID=23060703

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00918362A Ceased EP1171078A4 (de) 1999-03-26 2000-03-24 Zusammensetzungen und verfahren zur beeinflussung der blutspiegel von high density lipoprotein (hdl) cholesterol und apolipoprotein ai, very low density liporotein (vldl) cholesterol und low density lipoprotein (ldl) cholesterol

Country Status (13)

Country Link
EP (1) EP1171078A4 (de)
JP (1) JP2002540127A (de)
KR (2) KR20050044812A (de)
AU (1) AU776684B2 (de)
BR (1) BR0009333A (de)
CA (1) CA2363486C (de)
HK (1) HK1043309A1 (de)
IL (2) IL145526A0 (de)
MX (1) MXPA01009727A (de)
NO (2) NO331779B1 (de)
NZ (2) NZ531180A (de)
WO (1) WO2000057837A2 (de)
ZA (1) ZA200107598B (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507808B2 (en) * 2002-12-12 2009-03-24 Isis Pharmaceuticals, Inc. Modulation of endothelial lipase expression
US8288354B2 (en) 2005-12-28 2012-10-16 The Scripps Research Institute Natural antisense and non-coding RNA transcripts as drug targets
EP2370579B1 (de) 2008-12-04 2017-03-29 CuRNA, Inc. Behandlung von erythropoetin (epo)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen epo
WO2010065787A2 (en) 2008-12-04 2010-06-10 Curna, Inc. Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
CA2746003C (en) 2008-12-04 2020-03-31 Opko Curna, Llc Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
CA2752237C (en) 2009-02-12 2020-03-24 Opko Curna, Llc Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
EP2408919B1 (de) 2009-03-16 2017-10-18 CuRNA, Inc. Behandlung von erkrankungen im zusammenhang mit dem nuklearfaktor (erythroid-derived)-like 2 (nrf2) mittels hemmung des natürlichen antisense-transkripts gegen nrf2
MX2011009752A (es) 2009-03-17 2011-09-29 Opko Curna Llc Tratamiento de enfermedades relacionadas a homologo tipo delta 1(dlk1) por inhibicion de transcrito antisentido natural a homologo tipo delta (dlk1).
US9155754B2 (en) 2009-05-06 2015-10-13 Curna, Inc. Treatment of ABCA1 gene related diseases by inhibition of a natural antisense transcript to ABCA1
WO2010129746A2 (en) 2009-05-06 2010-11-11 Curna, Inc. Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
JP5931720B2 (ja) 2009-05-08 2016-06-08 クルナ・インコーポレーテッド Ｄｍｄファミリーに対する天然アンチセンス転写物の抑制によるジストロフィンファミリー関連疾患の治療
NO2432881T3 (de) 2009-05-18 2018-04-14
US8895527B2 (en) 2009-05-22 2014-11-25 Curna, Inc. Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2(IRS2) related diseases by inhibition of natural antisense transcript to TFE3
EP2435571B1 (de) 2009-05-28 2016-12-14 CuRNA, Inc. Behandlung von durch antivirale gene bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen ein antivirales gen
WO2010148050A2 (en) 2009-06-16 2010-12-23 Curna, Inc. Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
KR101702689B1 (ko) 2009-06-16 2017-02-06 큐알엔에이, 인크. Ｐｏｎ1에 대한 천연 안티센스 전사체의 억제에 의한 파라옥소나제 1(ｐｏｎ1) 관련된 질환의 치료
WO2010151671A2 (en) 2009-06-24 2010-12-29 Curna, Inc. Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
JP5907866B2 (ja) 2009-06-26 2016-04-26 クルナ・インコーポレーテッド ダウン症候群遺伝子に対する天然アンチセンス転写物の抑制によるダウン症候群遺伝子関連疾患の治療
US20120252869A1 (en) 2009-07-24 2012-10-04 Opko Curna, Llc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
KR101802536B1 (ko) 2009-08-05 2017-11-28 큐알엔에이, 인크. 인슐린 유전자 (ｉｎｓ)에 대한 자연 안티센스 전사체의 저해에 의한 인슐린 유전자 (ｉｎｓ) 관련된 질환의 치료
CN104313027B (zh) 2009-08-11 2018-11-20 库尔纳公司 通过抑制脂连蛋白(adipoq)的天然反义转录物治疗脂连蛋白(adipoq)相关疾病
CN102482670B (zh) 2009-08-21 2018-06-15 库尔纳公司 通过抑制‘hsp70-相互作用蛋白的c末端’(chip)的天然反义转录物而治疗chip相关疾病
KR101892760B1 (ko) 2009-08-25 2018-08-28 큐알엔에이, 인크. ＩＱＧＡＰ에 대한 천연 안티센스 전사체의 억제에 의한 ＧＴＰａｓｅ 활성화 단백질을 함유하는 ＩＱ 모티프(ＩＱＧＡＰ)와 관련된 질환의 치료
US20120295952A1 (en) 2009-09-25 2012-11-22 Curna, Inc. Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
US9173895B2 (en) 2009-12-16 2015-11-03 Curna, Inc. Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1
JP5934106B2 (ja) 2009-12-23 2016-06-15 カッパーアールエヌエー，インコーポレイテッド 肝細胞増殖因子（ｈｇｆ）に対する天然アンチセンス転写物の阻害によるｈｇｆ関連性疾患の治療
CA2782375C (en) 2009-12-23 2023-10-31 Opko Curna, Llc Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
CA2785177C (en) 2009-12-29 2019-09-24 Curna, Inc. Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
WO2011090740A2 (en) 2009-12-29 2011-07-28 Opko Curna, Llc Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
RU2616283C2 (ru) 2009-12-31 2017-04-13 Курна, Инк. Лечение заболеваний, связанных с субстратом рецептора инсулина 2 (irs2), путем ингибирования природного антисмыслового транскрипта к irs2
DK2521784T3 (en) 2010-01-04 2018-03-12 Curna Inc TREATMENT OF INTERFERON REGULATORY FACTOR 8- (IRF8) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPT TO IRF8
WO2011085066A2 (en) 2010-01-06 2011-07-14 Curna, Inc. Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
DK2524039T3 (en) 2010-01-11 2018-03-12 Curna Inc TREATMENT OF GENDER HORMON-BINDING GLOBULIN (SHBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS TO SHBG
WO2011091390A2 (en) 2010-01-25 2011-07-28 Opko Curna, Llc Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
US8962586B2 (en) 2010-02-22 2015-02-24 Curna, Inc. Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1
TWI600759B (zh) 2010-04-02 2017-10-01 可娜公司 藉由抑制群落刺激因子３（ｃｓｆ３）之天然反義轉錄物以治療ｃｓｆ３相關疾病
TWI644675B (zh) 2010-04-09 2018-12-21 可娜公司 藉由抑制纖維母細胞生長因子２１（ｆｇｆ２１）之天然反義轉錄物以治療ｆｇｆ２１相關疾病
RU2693462C2 (ru) 2010-05-03 2019-07-03 Курна, Инк. Лечение заболеваний, связанных с сиртуином (sirt), путем ингибирования природного антисмыслового транскрипта к сиртуину (sirt)
TWI586356B (zh) 2010-05-14 2017-06-11 可娜公司 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
WO2011150005A2 (en) 2010-05-26 2011-12-01 Opko Curna Llc Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
DK2576784T3 (en) 2010-05-26 2018-02-26 Curna Inc TREATMENT OF METHIONIN SULPHOXIDE REDUCTASE A (MSRA) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTION TO MSRA
JP6023705B2 (ja) 2010-06-23 2016-11-09 カッパーアールエヌエー，インコーポレイテッド ナトリウムチャネル、電位依存性、αサブユニット（ＳＣＮＡ）に対する天然アンチセンス転写物の阻害によるＳＣＮＡ関連疾患の治療
JP5998131B2 (ja) 2010-07-14 2016-09-28 カッパーアールエヌエー，インコーポレイテッド Ｄｉｓｃｓｌａｒｇｅｈｏｍｏｌｏｇ（ｄｌｇ）ｄｌｇ１への天然アンチセンス転写物の阻害によるｄｌｇ関連疾患の治療
US8993533B2 (en) 2010-10-06 2015-03-31 Curna, Inc. Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4
RU2597972C2 (ru) 2010-10-22 2016-09-20 Курна Инк. Лечение заболеваний, связанных с геном альфа-l-идуронидазы (idua), путем ингибирования природного антисмыслового транскрипта гена idua
WO2012068340A2 (en) 2010-11-18 2012-05-24 Opko Curna Llc Antagonat compositions and methods of use
EP2643463B1 (de) 2010-11-23 2017-09-27 CuRNA, Inc. Behandlung von nanog-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen nanog
JP6188686B2 (ja) 2011-06-09 2017-08-30 カッパーアールエヌエー，インコーポレイテッド フラタキシン（ｆｘｎ）への天然アンチセンス転写物の阻害によるｆｘｎ関連疾患の治療
CA2847811C (en) 2011-09-06 2019-10-22 Curna, Inc. Treatment of diseases related to alpha subunits of sodium channels, voltage-gated (scnxa) with small molecules
PT2825648T (pt) 2012-03-15 2018-11-09 Scripps Research Inst Tratamento de doenças relacionadas ao fator neurotrófico derivado do cerebro (bdnf) por inibição da transcrição anti-sentido natural ao bdnf
CN102628060A (zh) * 2012-03-22 2012-08-08 北京济福霖生物技术有限公司 一种低脂奶的生产方法
WO2014069651A1 (ja) 2012-11-05 2014-05-08 塩野義製薬株式会社 Ｅｌ活性が関連する疾患の治療または予防効果を有する医薬の薬効評価方法及びｅｌ活性阻害物質のスクリーニング方法
EP2975060A4 (de) 2013-03-14 2017-02-22 Shionogi & Co., Ltd. Monoklonaler antikörper zur hemmung der enzymatischen aktivität von endothellipase
TWI734410B (zh) 2014-09-11 2021-07-21 日商塩野義製藥股份有限公司 阻礙血管內皮脂酶之酵素活性的人類化單株抗體
MX2023008826A (es) 2021-02-01 2023-09-15 Regenxbio Inc Terapia génica para lipofuscinosis neuronal ceroidea.
EP4378480A1 (de) * 2021-07-26 2024-06-05 Purotech Bio, Inc. Anti-hepatitis-b-virus-mittel gegen wirtsfaktor-lipg

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024888A2 (en) * 1996-12-06 1998-06-11 Rhone-Poulenc Rorer Pharmaceuticals Inc. Polypeptides encoded by a human lipase-like gene, compositions and methods
WO1999032611A1 (en) * 1997-12-19 1999-07-01 Progenitor, Inc. A lipase expressed in endothelial cells and methods for its use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08507203A (ja) * 1992-12-04 1996-08-06 イノーバー ラボラトリーズ，インコーポレイテッド 調節可能な核酸治療およびそれらの使用方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024888A2 (en) * 1996-12-06 1998-06-11 Rhone-Poulenc Rorer Pharmaceuticals Inc. Polypeptides encoded by a human lipase-like gene, compositions and methods
WO1999032611A1 (en) * 1997-12-19 1999-07-01 Progenitor, Inc. A lipase expressed in endothelial cells and methods for its use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HIRATA KEN-ICHI ET AL: "Cloning of a unique lipase from endothelial cells extends the lipase gene family", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 274, no. 20, 14 May 1999 (1999-05-14), pages 14170 - 14175, XP002195654, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
NO20014657L (no) 2001-11-21
KR100887164B1 (ko) 2009-03-10
KR20020029651A (ko) 2002-04-19
WO2000057837A2 (en) 2000-10-05
NZ514350A (en) 2004-12-24
NO331779B1 (no) 2012-03-26
CA2363486C (en) 2012-12-18
BR0009333A (pt) 2002-01-08
MXPA01009727A (es) 2002-07-22
JP2002540127A (ja) 2002-11-26
NO20100214L (no) 2001-11-21
AU3918700A (en) 2000-10-16
NO331784B1 (no) 2012-03-26
IL145526A (en) 2010-11-30
HK1043309A1 (zh) 2002-09-13
IL145526A0 (en) 2002-06-30
NZ531180A (en) 2005-06-24
ZA200107598B (en) 2003-05-28
CA2363486A1 (en) 2000-10-05
EP1171078A2 (de) 2002-01-16
WO2000057837A3 (en) 2001-01-25
NO20014657D0 (no) 2001-09-25
WO2000057837A8 (en) 2001-09-27
AU776684B2 (en) 2004-09-16
WO2000057837A9 (en) 2001-10-18
KR20050044812A (ko) 2005-05-12

Similar Documents

Publication Publication Date Title
EP1171078A4 (de) Zusammensetzungen und verfahren zur beeinflussung der blutspiegel von high density lipoprotein (hdl) cholesterol und apolipoprotein ai, very low density liporotein (vldl) cholesterol und low density lipoprotein (ldl) cholesterol
EE200300136A (et) Kompositsioonid ja meetodid lipoproteiin (a) taseme alandamiseks plasmas ja kardiovaskulaarsete haiguste riskifaktorite vähendamiseks
HK1049723A1 (zh) 用於因特網、內聯網和本地觀察虛擬顯微鏡切片的裝置和方法
GB0114989D0 (en) Web server apparatus for virus checking
IL140989A0 (en) Compositions and methods for treating osteoporosis and lowering cholesterol
IL143829A0 (en) Method and apparatus for the dynamic filtering and routing of events
DE69909263D1 (de) Kontinuierliches entfernen flüchtiger bestandteile aus suspensionspolymerisation
AU4307799A (en) Apparatus and method for confinement and damping of vibration energy
AU2002330154A1 (en) Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
AP2002002704A0 (en) Methods and compositions for treating hepatitis c virus
AU2002230042A1 (en) Method and apparatus for efficient routing of mobile node packets
AU2001251376A1 (en) Stability enhanced water-in-oil emulsion and method for using same
NO20004582D0 (no) Sammensetninger og fremgangsmÕter for sementering ved anvendelse av elastiske partikler
AU2001252276A1 (en) Method for reducing the spread of computer viruses in an electronic mail network
AU4228600A (en) Compositions and methods for removing pollutants from contaminated materials
DK1383733T3 (da) Fremgangsmåde til fremstilling af 1,3-substituerede indener og aryl-sammenföjede azapolycykliske forbindelser
AU6927400A (en) Method and apparatus for improving stability of moving webs
AU2001289842A1 (en) Method and apparatus for managing traffic flows
AU2002326788A1 (en) Method for discovering new infectious particles
AU2002221657A1 (en) Method and system for preventing the spread of computer viruses
DK0885208T3 (da) Taxoider, fremstilling af disse forbindelser og farmaceutiske præparater indeholdende disse forbindelser
AU3065999A (en) Compositions and methods for treatment of asthma
AU1924301A (en) Method for operating an integrated point of presence server network
AU2002217033A1 (en) Method for developing and managing large-scale web user interfaces
AU1614700A (en) Method of generating aqueous silica network particles and compositions includingthe silica network particles

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011017

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20020925

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 6/00 A, 7C 12N 9/20 B

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AVENTIS PHARMACEUTICALS PRODUCTS INC.

Owner name: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

17Q First examination report despatched

Effective date: 20040915

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

Owner name: AVENTIS PHARMACEUTICALS INC.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KRAWIEC, JOHN, A.

Inventor name: MARCHADIER, DAWN

Inventor name: MAUGEAIS, CYRILLE

Inventor name: RADER, DANIEL, J.

Inventor name: JAYE, MICHAEL

Inventor name: SOUTH, VICTORIA, J.

Inventor name: LYNCH, KEVIN, J.

Inventor name: AMIN, DILIP, V.

Inventor name: DOAN, KIM-ANH, THI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AVENTIS PHARMACEUTICALS, INC.

Owner name: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LYNCH, KEVIN, J.

Inventor name: RADER, DANIEL, J.

Inventor name: KRAWIEC, JOHN, A.

Inventor name: DOAN, KIM-ANH, THI

Inventor name: MAUGEAIS, CYRILLE

Inventor name: MARCHADIER, DAWN

Inventor name: AMIN, DILIP, V.

Inventor name: JAYE, MICHAEL

Inventor name: SOUTH, VICTORIA, J.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AVENTIS PHARMACEUTICALS INC.

Owner name: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

APBK Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNE

APBN Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2E

APBR Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3E

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20130906

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1043309

Country of ref document: HK